Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA approves Otsuka/Lundbeck atypical antipsychotic Rexulti

This article was originally published in Scrip

Executive Summary

The FDA late on 10 July approved Otsuka's and Lundbeck's new drug application (NDA) to market Rexulti (brexpiprazole), an atypical antipsychotic, as adjunctive treatment for adults with major depressive disorder (MDD), which affects about 15 million adults in the US, and as a treatment for adults with schizophrenia, which affects about 2.4 million American adults.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts